SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
2.2B EUR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
194.7B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.8B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
138.8T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.3B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.8B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
167.6B HKD |
Loading...
|
Market Distribution
| Min | -222 027.4% |
| 30th Percentile | -2% |
| Median | 2.2% |
| 70th Percentile | 6% |
| Max | 85 055.6% |
Other Profitability Ratios
SCHOTT Pharma AG & Co KgaA
Glance View
SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe. SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for SCHOTT Pharma AG & Co KgaA is 15.1%, which is below its 3-year median of 15.6%.
Over the last 2 years, SCHOTT Pharma AG & Co KgaA’s Net Margin has decreased from 16.9% to 15.1%. During this period, it reached a low of 14% on Dec 31, 2024 and a high of 17.4% on Dec 31, 2023.